Link Pharma Chem Intrinsic Value
Link Pharma Chem (LINKPH) median intrinsic value is ₹52.00 from 3 valuation models (range ₹33–₹70), vs current price ₹28.06 — +85.3% upside (Trading Below Calculated Value), margin of safety 46.0%. Browse LINKPH financial statements for revenue, profit, balance sheet and cash flow data.
LINKPH Valuation Methods Summary — DCF, Graham Number & P/E
Link Pharma Chem intrinsic value across 3 models vs current price ₹28.06 — upside/downside and value range per method. For current market price and key ratios, visit Link Pharma Chem stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹32.50 | ₹29.25 - ₹35.75 | +15.8% | Book Value/Share: ₹32.50, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹52.00 | ₹46.80 - ₹57.20 | +85.3% | Revenue/Share: ₹65.00, P/S: 0.8x |
| Simple DCF (5Y) | dcf | ₹69.63 | ₹55.70 - ₹83.56 | +148.1% | CF Growth: 5.0%, Discount: 15% |
LINKPH Intrinsic Value vs Market Price — All Valuation Models
Link Pharma Chem fair value range ₹33–₹70 vs current market price ₹28.06 across 3 valuation models. Also explore LINKPH share price charts to track price trends across different timeframes.
LINKPH Intrinsic Value Analysis — Undervalued or Overvalued?
Link Pharma Chem median intrinsic value ₹52.00, current price ₹28.06 — Trading Below Calculated Value by 85.3%, margin of safety 46.0%.
What is the intrinsic value of LINKPH?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of Link Pharma Chem (LINKPH) is ₹52.00 (median value). With the current market price of ₹28.06, this represents a +85.3% variance from our estimated fair value.
The valuation range spans from ₹32.50 to ₹69.63, indicating ₹32.50 - ₹69.63.
Is LINKPH undervalued or overvalued?
Based on our multi-method analysis, Link Pharma Chem (LINKPH) appears to be trading below calculated value by approximately 85.3%.
LINKPH Financial Health — Key Ratios vs Industry Benchmarks
Link Pharma Chem financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 11.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -7.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 1.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.13x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
LINKPH Cash Flow Quality — Operating & Free Cash Flow
Link Pharma Chem operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-1 Cr | ₹-4 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹5 Cr | ₹4 Cr | Positive Free Cash Flow | 8/10 |